$AMED
AMEDISYS INC

2023 Q2 Form 10-Q Financial Statement

#000089626223000045 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $553.0M $556.4M $545.3M
YoY Change -0.88% 2.04% 1.52%
Cost Of Revenue $297.5M $315.0M $304.8M
YoY Change -5.93% 3.35% 2.56%
Gross Profit $255.5M $241.5M $244.4M
YoY Change 4.43% -1.2% 1.89%
Gross Profit Margin 46.21% 43.4% 44.83%
Selling, General & Admin $213.0M $194.6M $184.5M
YoY Change 13.4% 5.47% 7.12%
% of Gross Profit 83.36% 80.56% 75.47%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $6.199M $5.694M $8.008M
YoY Change -0.34% -28.9% 6.0%
% of Gross Profit 2.43% 2.36% 3.28%
Operating Expenses $217.7M $199.0M $192.5M
YoY Change 12.2% 3.39% 7.05%
Operating Profit $37.80M $42.40M $48.00M
YoY Change -20.6% -11.67% -30.23%
Interest Expense $1.231M $7.517M $3.173M
YoY Change -85.19% 136.91% 53.14%
% of Operating Profit 3.26% 17.73% 6.61%
Other Income/Expense, Net $4.743M -$7.670M -$4.230M
YoY Change -165.11% 81.32% 558.88%
Pretax Income -$62.23M $34.71M $43.73M
YoY Change -254.21% -20.63% -35.88%
Income Tax $18.25M $9.800M $12.02M
% Of Pretax Income 28.23% 27.48%
Net Earnings -$80.28M $25.25M $31.67M
YoY Change -371.39% -20.29% -36.49%
Net Earnings / Revenue -14.52% 4.54% 5.81%
Basic Earnings Per Share -$2.46 $0.78 $0.97
Diluted Earnings Per Share -$2.46 $0.77 $0.97
COMMON SHARES
Basic Shares Outstanding 32.56M shares 32.55M shares 32.56M shares
Diluted Shares Outstanding 32.58M shares 32.64M shares 32.77M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $95.38M $49.44M $67.83M
YoY Change 259.02% -27.12% -12.25%
Cash & Equivalents $95.38M $49.40M $67.80M
Short-Term Investments
Other Short-Term Assets $52.38M $23.58M $10.78M
YoY Change 105.48% 118.83% -2.26%
Inventory
Prepaid Expenses $13.77M $18.75M $17.22M
Receivables $278.8M $294.1M $293.6M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $426.5M $405.6M $392.5M
YoY Change 8.02% 3.33% 3.16%
LONG-TERM ASSETS
Property, Plant & Equipment $121.5M $33.35M $17.30M
YoY Change 581.02% 92.85% -20.22%
Goodwill $1.245B $1.245B $1.205B
YoY Change -3.49% 3.32% 29.09%
Intangibles $104.7M $99.93M $106.5M
YoY Change -1.36% -6.2% 52.71%
Long-Term Investments $65.90M $58.90M $65.00M
YoY Change 1.38% -9.38% 371.01%
Other Assets $18.99M $78.23M $84.64M
YoY Change -77.57% -7.57% 157.16%
Total Long-Term Assets $1.556B $1.541B $1.516B
YoY Change -3.13% 1.68% 27.09%
TOTAL ASSETS
Total Short-Term Assets $426.5M $405.6M $392.5M
Total Long-Term Assets $1.556B $1.541B $1.516B
Total Assets $1.982B $1.947B $1.908B
YoY Change -0.93% 2.02% 21.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $38.56M $40.02M $36.62M
YoY Change -11.38% 9.27% -5.77%
Accrued Expenses $286.4M $137.9M $148.0M
YoY Change 62.49% -6.85% -13.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $31.47M $26.90M $12.30M
YoY Change 151.72% 118.7% 19.42%
Total Short-Term Liabilities $462.4M $353.1M $380.2M
YoY Change 8.2% -7.13% -16.65%
LONG-TERM LIABILITIES
Long-Term Debt $369.9M $373.2M $429.5M
YoY Change -16.39% -13.11% 85.61%
Other Long-Term Liabilities $61.26M $4.781M $4.923M
YoY Change 356.91% -2.88% -85.0%
Total Long-Term Liabilities $431.2M $378.0M $434.4M
YoY Change -5.41% -12.99% 64.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $462.4M $353.1M $380.2M
Total Long-Term Liabilities $431.2M $378.0M $434.4M
Total Liabilities $975.6M $813.6M $887.7M
YoY Change 1.42% -8.35% 13.28%
SHAREHOLDERS EQUITY
Retained Earnings $702.6M $782.9M $670.7M
YoY Change 0.33% 16.73% 39.78%
Common Stock $768.8M $758.7M $736.5M
YoY Change 3.43% 3.01% 4.18%
Preferred Stock
YoY Change
Treasury Stock (at cost) $464.7M $462.5M $440.6M
YoY Change 1.46% 4.98% 10.48%
Treasury Stock Shares 5.197M shares
Shareholders Equity $1.007B $1.079B $966.8M
YoY Change
Total Liabilities & Shareholders Equity $1.982B $1.947B $1.908B
YoY Change -0.93% 2.02% 21.31%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$80.28M $25.25M $31.67M
YoY Change -371.39% -20.29% -36.49%
Depreciation, Depletion And Amortization $6.199M $5.694M $8.008M
YoY Change -0.34% -28.9% 6.0%
Cash From Operating Activities $60.76M $25.96M $48.62M
YoY Change 5.84% -46.61% -9.96%
INVESTING ACTIVITIES
Capital Expenditures $7.851M $1.350M $902.0K
YoY Change -456.38% 49.67% -44.25%
Acquisitions $350.0K $0.00
YoY Change
Other Investing Activities $106.0K $47.46M -$14.94M
YoY Change -100.14% -417.62% -15041.0%
Cash From Investing Activities -$7.745M $45.90M -$16.08M
YoY Change -89.74% -385.44% 932.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net $55.31M $3.771M
YoY Change 1366.8% 40.08%
Cash From Financing Activities -10.95M -$56.89M -$7.402M
YoY Change 170.71% 668.58% -87.12%
NET CHANGE
Cash From Operating Activities 60.76M $25.96M $48.62M
Cash From Investing Activities -7.745M $45.90M -$16.08M
Cash From Financing Activities -10.95M -$56.89M -$7.402M
Net Change In Cash 42.06M $14.97M $25.14M
YoY Change -289.93% -40.47% -601.5%
FREE CASH FLOW
Cash From Operating Activities $60.76M $25.96M $48.62M
Capital Expenditures $7.851M $1.350M $902.0K
Free Cash Flow $52.91M $24.61M $47.72M
YoY Change -11.25% -48.43% -8.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3854 American Way
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
AMEDISYS INC
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000896262
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
0-24260
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-3131700
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite A
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Baton Rouge
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
LA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
70816
CY2023Q1 dei City Area Code
CityAreaCode
225
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
292-2031
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
AMED
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32559388 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49436000 usd
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.77
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40540000 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
19664000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
13593000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
294122000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
296785000 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
18754000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11628000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
23581000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
26415000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
405557000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
388961000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
105183000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
101364000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
33353000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
16026000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
85211000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
102856000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
1244679000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
1287399000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
16071000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
14604000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
99929000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
101167000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
78230000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
79836000 usd
CY2023Q1 us-gaap Assets
Assets
1946959000 usd
CY2022Q4 us-gaap Assets
Assets
1976245000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
40017000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
43735000 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
122723000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
125387000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
137899000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
137390000 usd
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
26958000 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
15496000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
25453000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
33521000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
353050000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
355529000 usd
CY2023Q1 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
373202000 usd
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
419420000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
59826000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
69504000 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
22752000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
20411000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4781000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4808000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
813611000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
869672000 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2022Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 usd
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37938354 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37891186 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32544145 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32511465 shares
CY2023Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
38000 usd
CY2022Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
38000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
758669000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
755063000 usd
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5394209 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5379721 shares
CY2023Q1 us-gaap Treasury Stock Value
TreasuryStockValue
462508000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
461200000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
782918000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
757672000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1079117000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1051573000 usd
CY2023Q1 us-gaap Minority Interest
MinorityInterest
54231000 usd
CY2022Q4 us-gaap Minority Interest
MinorityInterest
55000000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1133348000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1106573000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1946959000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1976245000 usd
CY2023Q1 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
556389000 usd
CY2022Q1 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
545257000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
315010000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
304820000 usd
CY2023Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
126339000 usd
CY2022Q1 us-gaap Labor And Related Expense
LaborAndRelatedExpense
123480000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3273000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7347000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4443000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8008000 usd
CY2023Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
64945000 usd
CY2022Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
53640000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
514010000 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
497295000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
42379000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
47962000 usd
CY2023Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
406000 usd
CY2022Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
13000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
7517000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
3173000 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
123000 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1403000 usd
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-682000 usd
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
333000 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7670000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4230000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
34709000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
43732000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9800000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12019000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
24909000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
31713000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-337000 usd
CY2022Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
42000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
25246000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
31671000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.78
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.97
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32558000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32555000 shares
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.97
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32643000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32766000 shares
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1106573000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
816000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3273000 usd
CY2023Q1 amed Surrendered Shares
SurrenderedShares
1308000 usd
CY2023Q1 us-gaap Minority Interest Decrease From Redemptions
MinorityInterestDecreaseFromRedemptions
630000 usd
CY2023Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
285000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
24909000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1133348000 usd
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
976323000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
985000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
86000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7347000 usd
CY2022Q1 amed Surrendered Shares
SurrenderedShares
4682000 usd
CY2022Q1 amed Contributions Attributable To Noncontrolling Interest
ContributionsAttributableToNoncontrollingInterest
9552000 usd
CY2022Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
672000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
31713000 usd
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1020652000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
24909000 usd
CY2022Q1 us-gaap Profit Loss
ProfitLoss
31713000 usd
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5694000 usd
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8008000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3273000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7347000 usd
CY2023Q1 amed Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
8622000 usd
CY2022Q1 amed Amortizationand Impairmentof Operating Lease Right Of Use Asset
AmortizationandImpairmentofOperatingLeaseRightOfUseAsset
10096000 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
70000 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-5000 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-2186000 usd
CY2022Q1 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
0 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
2772000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
3205000 usd
CY2023Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
123000 usd
CY2022Q1 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-1403000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
248000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
248000 usd
CY2023Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
1787000 usd
CY2022Q1 us-gaap Equity Method Investment Dividends Or Distributions
EquityMethodInvestmentDividendsOrDistributions
1710000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7476000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
18618000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4128000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7882000 usd
CY2023Q1 amed Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-918000 usd
CY2022Q1 amed Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-749000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
111000 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-247000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3457000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2115000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
741000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7483000 usd
CY2023Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-28000 usd
CY2022Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-57000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-7960000 usd
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-9187000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
25961000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
48621000 usd
CY2023Q1 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
19000 usd
CY2022Q1 us-gaap Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
22000 usd
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
CY2022Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
37000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1350000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
902000 usd
CY2023Q1 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
210000 usd
CY2022Q1 us-gaap Payments To Develop Software
PaymentsToDevelopSoftware
236000 usd
CY2023Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
0 usd
CY2022Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
15000000 usd
CY2023Q1 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
47787000 usd
CY2022Q1 us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
0 usd
CY2023Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
350000 usd
CY2022Q1 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45896000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16079000 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
86000 usd
CY2023Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
816000 usd
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
985000 usd
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1308000 usd
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4682000 usd
CY2023Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0 usd
CY2022Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
652000 usd
CY2023Q1 amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
285000 usd
CY2022Q1 amed Cash Distribution To Noncontrolling Interest
CashDistributionToNoncontrollingInterest
672000 usd
CY2023Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
8000000 usd
CY2022Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 usd
CY2023Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
8000000 usd
CY2022Q1 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
0 usd
CY2023Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
55313000 usd
CY2022Q1 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3771000 usd
CY2023Q1 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
800000 usd
CY2022Q1 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
0 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-56890000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-7402000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
14967000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
25140000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54133000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45769000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69100000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
70909000 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
6654000 usd
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1864000 usd
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
352000 usd
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
551000 usd
CY2023Q1 amed Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
8878000 usd
CY2022Q1 amed Cash Paid For Operating Lease Liabilities
CashPaidForOperatingLeaseLiabilities
9936000 usd
CY2023Q1 amed Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
2457000 usd
CY2022Q1 amed Cash Paid For Finance Lease Liabilities
CashPaidForFinanceLeaseLiabilities
357000 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7083000 usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
11203000 usd
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
20790000 usd
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
216000 usd
CY2023Q1 amed Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
141000 usd
CY2022Q1 amed Lessee Operatinglease Reductionsto Ro Uassetsresultingfromreductionstoleaseobligations
LesseeOperatingleaseReductionstoROUassetsresultingfromreductionstoleaseobligations
299000 usd
CY2023Q1 amed Lessee Finance Lease Reductions To Rou Assets Resulting From Reductions To Finance Lease Obligations
LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations
369000 usd
CY2022Q1 amed Lessee Finance Lease Reductions To Rou Assets Resulting From Reductions To Finance Lease Obligations
LesseeFinanceLeaseReductionsToROUAssetsResultingFromReductionsToFinanceLeaseObligations
0 usd
CY2023Q1 amed Non Cash Noncontrolling Interest Contribution
NonCashNoncontrollingInterestContribution
0 usd
CY2022Q1 amed Non Cash Noncontrolling Interest Contribution
NonCashNoncontrollingInterestContribution
8900000 usd
CY2023Q1 us-gaap Number Of States In Which Entity Operates
NumberOfStatesInWhichEntityOperates
37 state
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting and reporting policies conform with U.S. GAAP. In preparing the unaudited condensed consolidated financial statements, we are required to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></div>
CY2023Q1 amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2023Q1 us-gaap Comparability Of Prior Year Financial Data
ComparabilityOfPriorYearFinancialData
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to prior periods' financial statements in order to conform to the current year presentation. These reclassifications had no effect on our previously reported net income. See Note 8 - Segment Information for additional information regarding these reclassifications.</span></div>
CY2023Q1 amed Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
0.99
CY2023Q1 amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
CY2022Q1 amed Revenuebypayorclassasapercentageoftotalnetservicerevenue
Revenuebypayorclassasapercentageoftotalnetservicerevenue
1
CY2023Q1 amed Net Service Revenue Episode Payment Rate Duration
NetServiceRevenueEpisodePaymentRateDuration
P60D
CY2023Q1 amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2023Q1 amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2023Q1 amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2023Q1 amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2023Q1 amed Percentage Of Total Reimbursement Of Outlier Payment
PercentageOfTotalReimbursementOfOutlierPayment
0.10
CY2023Q1 amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2023Q1 amed Net Service Revenue Period Of Care Payment Rate Duration
NetServiceRevenuePeriodOfCarePaymentRateDuration
P30D
CY2023Q1 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
CY2022Q1 amed Hospice Medicare Revenue Rate Accounted For Routine Care
HospiceMedicareRevenueRateAccountedForRoutineCare
0.97
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49400000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40500000 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
19700000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
13600000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69100000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54100000 usd
CY2023Q1 amed Percentage Of Patient Receivables Outstanding
PercentageOfPatientReceivablesOutstanding
0.10
CY2023Q1 amed Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
0.67
CY2022Q4 amed Accounts Receivable Portion Derived From Medicare
AccountsReceivablePortionDerivedFromMedicare
0.67
CY2023Q1 amed Historical Collection Rate From Medicare
HistoricalCollectionRateFromMedicare
0.99
CY2023Q1 amed Debt Instrument Carrying Amount Excluding Finance Leases
DebtInstrumentCarryingAmountExcludingFinanceLeases
383300000 usd
CY2023Q1 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
38900000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32558000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32555000 shares
CY2023Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
13000 shares
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
65000 shares
CY2023Q1 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
72000 shares
CY2022Q1 amed Non Vested Stock And Stock Units
NonVestedStockAndStockUnits
146000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32643000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32766000 shares
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
323000 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
188000 shares
CY2023Q1 amed Minimum Percent Ownership For Controlling Interest Percent
MinimumPercentOwnershipForControllingInterestPercent
0.50
CY2023Q1 amed Maximum Percent Ownership For Equity Method Percent
MaximumPercentOwnershipForEquityMethodPercent
0.50
CY2023Q1 amed Total Leverage Ratio
TotalLeverageRatio
1.6
CY2022Q4 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
40500000 usd
CY2023Q1 amed Maximum Percent Ownership For Cost Method Percent
MaximumPercentOwnershipForCostMethodPercent
0.20
CY2022Q1 us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
15000000 usd
CY2023Q1 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
20000000 usd
CY2022Q4 us-gaap Investment Owned At Cost
InvestmentOwnedAtCost
20000000 usd
CY2023Q1 amed Consolidated Interest Coverage Ratio
ConsolidatedInterestCoverageRatio
10.3
CY2023Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
403400000 usd
CY2022Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
438400000 usd
CY2023Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3300000 usd
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
3500000 usd
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
400100000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
434900000 usd
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
26900000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
15500000 usd
CY2023Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
373200000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
419400000 usd
CY2023Q1 amed Reclassification Of Operating Lease To Finance Lease
ReclassificationOfOperatingLeaseToFinanceLease
15000000 usd
CY2023Q1 amed Health Insurance Retention Limit
HealthInsuranceRetentionLimit
1300000 usd
CY2023Q1 amed Workers Compensation Insurance Retention Limit
WorkersCompensationInsuranceRetentionLimit
2000000 usd
CY2023Q1 amed Professional Liability Insurance Retention Limit
ProfessionalLiabilityInsuranceRetentionLimit
300000 usd
CY2023Q1 amed Fleet Insurance Exposure Limit
FleetInsuranceExposureLimit
400000 usd
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4 segments
CY2023Q1 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
556400000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
315000000.0 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
194600000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4400000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
514000000.0 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
42400000 usd
CY2022Q1 us-gaap Health Care Organization Revenue Net Of Patient Service Revenue Provisions
HealthCareOrganizationRevenueNetOfPatientServiceRevenueProvisions
545300000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
304800000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
184500000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
8000000.0 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
497300000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
48000000.0 usd

Files In Submission

Name View Source Status
0000896262-23-000045-index-headers.html Edgar Link pending
0000896262-23-000045-index.html Edgar Link pending
0000896262-23-000045.txt Edgar Link pending
0000896262-23-000045-xbrl.zip Edgar Link pending
amed-20230331.htm Edgar Link pending
amed-20230331.xsd Edgar Link pending
amed-20230331_g1.jpg Edgar Link pending
amed-20233103xexx311.htm Edgar Link pending
amed-20233103xexx312.htm Edgar Link pending
amed-20233103xexx321.htm Edgar Link pending
amed-20233103xexx322.htm Edgar Link pending
exhibit101_separationagree.htm Edgar Link pending
exhibit102thirdamendmentto.htm Edgar Link pending
exhibit21_equitypurchaseag.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
amed-20230331_cal.xml Edgar Link unprocessable
amed-20230331_pre.xml Edgar Link unprocessable
amed-20230331_def.xml Edgar Link unprocessable
amed-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
amed-20230331_htm.xml Edgar Link completed
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending